chrisvoncsefalvay/vaers-outcomes huggingface dataset:
majority those tested have receive all four Pfizer testing positive including himself or herself; majority those tested have receive all four Pfizer testing positive including himself or herself; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "majority those tested have receive all four Pfizer testing positive including himself or herself". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: receive all four Pfizer testing positive including himself or herself.  Additional information: The organization an avid supporter of constituency receiving Pfizer regular and booster shot. Himself or herself and majority organization receive both regular and two boosters. The administration during random COVID testing, test administered majority those tested have receive all four Pfizer testing positive including himself or herself. This having attack credibility in supporting Pfizer testing.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5, BNT162b2 has been requested and will be submitted if and when received.
8 days after injection my arm/shoulder swelled up skin turned red was very warm and sore.  It got worse on day 9 then it started to subside on day 10, by day 12 I was ok.  Also I was fatigued, had headaches and a little nauseous at times.  This worried me until I went on the internet and found out there is something called "Covid Arm" that can happen days after the injection.  I wish I knew before hand so I didn't worry.
Blurry vision, light sensitivity, intermittent light headedness starting 3/22/2021,  Headache's  starting day after vaccine.
Arm soreness, muscle aches, headache, chills and fever  of 101.3 which began at 2:30 am on 2/3/2021 and lasted until 1:00 am on 2/4/2021 nausea began at the same time but is still ongoing.
Received 2 vaccines (flu, pneumonia) on 10/13/11. About 24 hrs later (L) arm (with injection) began to hurt, no redness. Took ADVIL and TYLENOL only helping a little with pain. On 10/15/11 (L) arm became red at site, pain continued, temp 99.5 F. On 10/16/11 (L) arm site increased redness with yellow in middle (?bruise or infection. Went to urgent care. Given KEFLEX 500 mg TID. Told to take prednisone if not better in 24 hrs or worse. Pt has prednisone from rheumatologists, psoriatic arthritis. 1 wk prior had tetanus shot in same arm as in the (R) breast cancer.
15 hours post Shingrix vaccine.  Developed fever 101-103 F..., chills, body aches, resting heart rate 108-113, headache, legs felt heavy when attempting to walk. Symptoms mimic the flu that lasted for 12 hours.
pt recvd vax on 31oct94 am; at 11:30am on 1nov94 laughing, playfull & took nap; at 1:15pm found in crib by pub hlth nurse cold & pulseness; to er, t 88.9 rectally; resucitation unsuccessful; pronounced dead at 2pm;
Red rash on left upper arm, swollen on the rash, itchy on the rash
Mild soreness on second day after first dose of vaccination.  The soreness was similar to a mild bruise or a stiff muscle.; Mild soreness on second day after first dose of vaccination.  The soreness was similar to a mild bruise or a stiff muscle.; Mild soreness on second day after first dose of vaccination.  The soreness was similar to a mild bruise or a stiff muscle.; This is a spontaneous report from a non-contactable consumer, the patient.   A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Lot Number: ER8737 and expiry date was not reported) via an unspecified route of administration, in left arm on 03Apr2021 at 15:15 (at the age of 33-year-old) as dose 1, single for COVID-19 immunisation. The patient medical history was not reported. The patient previously received SCOPOLAMINE PATCHES on an unknown date and experienced skin rash. The patient reported that it was unclear that whether she was allergic to medication or the adhesive (not allergic to any other adhesive). Concomitant medications included levonorgestrel (MIRENA IUD) and sodium fluoride (PREVIDENT TOOTHPASTE) all from unknown dates and for unknown indications. Patient was not pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 second day after first dose of vaccination, the patient experienced mild soreness. The soreness was similar to a mild bruise or a stiff muscle. The patient did not receive any treatment for the reported event. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event mild soreness similar to a mild bruise or a stiff muscle were recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Shingles; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Shingles) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, the patient experienced HERPES ZOSTER (Shingles). At the time of the report, HERPES ZOSTER (Shingles) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication included antiviral medication. The patient was scheduled for his second dose on Friday of the report week.   Reporter did not allow further contact
brief swelling at injection site, gave patient loratadine, swelling then started to decrease. Patients son (nurse) claimed to have seen this before and said it was a mild allergic reaction.  Called patient next day, said she was fine just a little sore.
received fluad twice, once on 9/20/23 and once on 9/27/23.
There was an excrusion from freezer; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (There was an excrusion from freezer) in a 49-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939901) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Oct-2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (There was an excrusion from freezer). On 25-Oct-2021, PRODUCT TEMPERATURE EXCURSION ISSUE (There was an excrusion from freezer) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   There was an excursion from the freezer on 01-Oct-2021 and the nurse used the excursion tool but there was no option for the excursion experienced. The only tool gave the options for excursion above one hour and not less than that so the nurse did not known about the analysis. The nurse stated that the team knew the recommended temperature and wanted to know whether the vials were still in a good condition to be used and were administered to 118 patients. The storage condition at the time of the excursion was frozen, vial size was 7.5 mL and maximum or minimum temperature mentioned as minimum minus 4.2 degree Fahrenheit and maximum 5.7 degree Fahrenheit. The excursion duration was 6 minutes. On visual inspection, the vials were thawed before administration and there were no color changes or anything abnormal. Total 10 vials or doses were impacted.  No concomitant medication was provided.            No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 15-Nov-2021: Follow up received on 15-Nov-2021 contain updated contact information, patient details and suspect product details
This report describes mercury poisoning in a male child, now 5 year old, who received Hepatitis b vaccine recombinant. It was received as part of litigation proceedings and has not been verified by a physician other healthcare professional. The child received injections of Enegrix on 07/25/96 and 02/27/97. He also received Hepatitis B vaccine; 06/27/95, Tetramune, 08/22/96,10/24/96 and 12/26/96;DTap, (date unknown); Hibtiter, 09/29/1997; Orimune, 08/22/96, 10/24/96, 12/26/96 and 12/29/97; MMRII, 09/29/97; Varivax, 12/29/97. The vaccinee's attorney alleged that "through his vaccinations administered during the period from 03/96 through 12/97, he was subjected to very high doses of the mercury contained in Thimersol. As a result of the mercury in the thimersol-containing vaccinations that he received as an infant, he now suffers, and in the future will continue to suffer, from the toxic neurological effects of mercury poisoning". Time to onset from immuni=zation and treatment were not provided
I experienced intense and painful burning sensation throughout my body overnight after having had the first dose of the vaccine in the morning. It felt like my nerves were inflamed and on fire. I was unable to sleep. The pain and burning sensation subsided the next morning but I was left with pain and stiffness in my hands and feet, particularly in my hands. I have had to soak my hands in very hot water to obtain relief and improve motion. It has been very difficult to type and move my hands like I was able to before I had the shot. I had experienced raynaud?s in the past which I had controlled by eliminating gluten but after the vaccine the raynaud?s returned rendering it uncomfortable to handle frozen food from the freezer.  I believe the shot has caused my diagnosis limited Scleroderma (autoimmune condition) to flare. It is August 14 and I am still experiencing these symptoms. I do not want to take the second dose of the vaccine  because of these side effects.  It is unknown at this time whether these side effects are permanent.
Patient stood for a few minutes after receiving vaccine while his sister was receiving hers.  He began "blacking out" as he described later, but it initially looked as if he may have a seizure.  The patient had a blank stare and then started leaning.  I let him go to the floor slowly and the mother came in the room and attended him until he regained awareness/consciousness.
Received 1st dose of HEP-B vax, 8/10/99, subsequently, in 8/99, pt experienced a grand mal seizure. On 9/28/99, pt was vax with 2nd dose of HEP-B vax. On 10/1/99, pt had lymphadenopathy. On 10/4/99, pt had generalized rash. Pt was seen 4 x
Patient received Pfizer COVID vaccine for first dose 7/7/21, was inadvertantly administered Moderna COVID vaccine for second dose. Per CDC guideline no subsequant dose was adminstered.  No adverse physical symptoms reported by patient.
dose reconstituted and not used within 6h; The vaccines was reconstituted and not used within the 6hs. Patient was vaccinated after the 6 hs period; This case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 80-year-old female patient who received Herpes zoster (Shingrix) (batch number 5A9GE, expiry date 3rd June 2023) for prophylaxis.   On 7th March 2022, the patient received Shingrix. On 7th March 2022, unknown after receiving Shingrix, the patient experienced wrong technique in drug usage process. On an unknown date, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug and wrong technique in drug usage process were unknown.  Additional details were provided as follows: Clinical supervisor reported that the patient was vaccinated with a dose of Shingrix which was reconstituted and not used within the 6 hours, which led to incorrect storage of drug. The patient was vaccinated after the 6 hours period of reconstitution, which led to wrong technique in drug usage process.  The reporter gave consent to follow-up.
Pt recv vax on 10/14/98; post vax pt exp tight throat, hoarse, red blotches on neck & chest
This literature marketed report as received from the authors of the published article, titled as stated below, refers to a 7 year old patient of unknown gender. The patient's concurrent conditions, medical history and concomitant medications were not reported.  On 03-DEC-2015, Public Health (PH) was notified by a local indergartengrade 2 school that a student aged 8 years (the index patient) had been sent home because of a rash suspected to be varicella (chickenpox); the rash had not been observed the previous day. The index patient rode a school bus and was the first student on and the last off each day. Public health investigators subsequently linked three more cases in children to sharing the same school bus as the index patient and they also received diagnoses of varicella. The first case was diagnosed in a student aged 7 years, who received an unspecified amount of doses (reported as fully immunized) of varicella virus vaccine live (oka/merck) (manufacturer unknown) injection (exact dose and route of administration were not reported) on unknown dates. On 15-DEC-2015, the patient had rash onset. Diagnosis of varicella was subsequently (date unspecified) confirmed from a cutaneous lesion swab by polymerase chain reaction (PCR). This student rode on the same bus as the index patient for approximately 40 minutes in each direction each day. The patient was not related to or interacted socially with members of household of the index patient. It was not known whether the student sat next to or otherwise interacted with the index patient during the bus ride.  The reported coverage with at least 1 dose of varicella vaccine in the school was 96% and for coverage with 2 doses was 95%. The overall coverage rate with all required immunizations for the school was 95%; 2% of children had waivers, and immunizations for 3% of children were incomplete. This outbreak of varicella appeared to have begun with an adult case of herpes zoster and resulted in nine cases of varicella in children residing in three households. The timeline of rash onsets was consistent with the 1021 day incubation period for varicella. With continued 2-dose childhood varicella vaccination and declining incidence of varicella among children, transmission of varicella initiated by adults with herpes zoster could become increasingly more likely. This investigation also strongly suggested that transmission of varicella to children occurred while riding the same school bus as the index patient. Varicella transmission on school buses was plausible and was implicated previously as a risk factor for transmission in a large varicella outbreak reported in China. This investigation underscored the importance of maintaining high 2-dose varicella immunization levels to reduce risk for disease transmission. The high immunization rates achieved in this school likely limited the scope of the varicella outbreak. The outcome of the events was not reported. The reporters considered the events to be related to varicella virus vaccine live (oka/merck) (manufacturer unknown). Additional information has been requested.
full day of full body aches; chills; headache; miserable; This is a spontaneous report from a contactable consumer (patient). A 56-year-old female (not pregnant at the time of vaccination) patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (lot number EL0142), via an unspecified route of administration at left arm on 04Jan2021 14:45 at single dose for COVID-19 immunization at a workplace clinic. The patient's medical history was reported as none, no known allergies to medications, food, or other products and no other medical history. Concomitant medication in two weeks included progesterone, testosterone, colecalciferol (D3), calcium, "C", "E", and "Ty". No other vaccine within four weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination, and had not been tested for CPVOD-19 since the vaccination. On 04Jan2021 the patient received the injection. And on 05Jan2021, the patient experienced full day of full body aches, chills, headache, and miserable. No fever. The events started on 05Jan2021 05:00. On 06Jan2020, the patient felt great. No treatment was received for the events. The outcome of the events was recovered on 06Jan2021.
Chills, Fever, Vomiting, Muscle pains, shaking. Treatment included- Tylenol, Ibuprofen, Zofran and Morphine all administrated at the ER. Upon arrival pain scale was surpassed that of 1-10, but was at 15! Was present at the ER for over five hours, blood and urine tests were taken, test came back normal. Was recommended to treat as if it was the flu!
Whole body, itchy red rash, most intense in arms, hands, feet, knees, hips. Lasted 4 days.
Pt's R. arm at inj. site became swollen, red, itchy. Pt. also had hives on his face & neck, (about 20).
MUCUS POURING OUT OF EYES, 102' FEVER, EXTREMELY COLD, IMMOBILE.
This spontaneous report as received from a pharmacy technician refers to a multiple anonymous patients of unknown age. On an unknown date the patients were vaccinated with ROTATEQ (dose was not reported, route of administration defaulted to oral). On an unknown date the patients have been administered oral, ROTATEQ post supported excursion. No adverse effects noted by any patients. This is one of several reports from the same source. Additional information has been requested.
Fever 100 degrees;body aches;vomiting;painful feet (child unable to walk)
Two hours after getting the vaccination Pt. experienced hives all over her body. Still has some hives yet today
This spontaneous report as received from a nurse refers to an unspecified number of patients of unknown age and gender. Between 03-SEP-2014 and 30-SEP-2014 the patient was vaccinated with an improperly stored dose of VARIVAX (Merck) lot # J004160, expiration date: 05-APR-2015 (dose, lot# and route of administration were not reported). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Arm was very sore.  Felt nausea and very frigid for hours with a slight headache starting late in the afternoon after vaccine administered.  By next morning still had a slight headache and tired.  Within 36 hours felt much better.
pain at the injection site and tenderness that spread to her armpit; pain at the injection site and tenderness that spread to her armpit; pain at the injection site and tenderness that spread to her armpit; This spontaneous report was received from a pharmacist and refers to a 67-year-old female patient. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided. On 05-NOV-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) injection, intramuscularly, lot # T024669 with expiration date on 21-MAR-2020 (dose and anatomical localization were unknown) as it was recommended for the patient's age.  On 05-NOV-2020, after the injection, the patient started to experience pain and tenderness at the injection site, that spread to her armpit.  The patient did not sought medical attention and did not receive any treatment for the events. The outcome of the events was reported as not recovered.       The casual relationship between the events and suspect therapy was not reported.
Pain and swelling at ejection site throughout upper arm, shoulder and shoulder joint. Fatigue. Lightheadedness.
Information has been received from a physician concerning a 75 year old male with hypothyroidism, hypertension and penicillin allergy who on 15-JUL-2008 was vaccinated with a dose of ZOSTAVAX.  Concomitant therapy included levothyroxine Na and NORVASC.  On approximately 29-JUL-2008 the patient developed rash across the top of his back, that extends down his back.  The rash was also present on his ankles.  The patient was achy, feverish and experiencing chills.  The patient sought medical attention (office visit).  Complete blood cell count was performed which showed low white blood cell count.  At time of reporting, the patient had not recovered.  The reporter considered the events to be disabling.  Additional information has been requested.
Information has been received from a nurse practitioner concerning a 16 or 17 year old female who was vaccinated (date, route and site not reported) with Gardasil vaccine (lot # not reported) and tetanus toxoid (manufacturer unknown). Per the nurse practitioner, post vaccination, the patient fainted while leaving the office. The patient received unspecified medical attention and the outcome of the patient is unknown. Additional information has been requested.  Follow-up received 04/16/2008 from the office manager stating that the nurse practioner is not aware of the specific patient referenced. No additional information is expected.
Information has been received from a nurse concerning a female pt who on an unspecified date was vaccinated IM with HPV vaccine (it was reported that it was uncertain whether this was the pts first dose). Subsequently, the day after vaccination, the pt experienced flu-like symptoms, felt horrible and felt very sick for a few days. At the time of this report, the pt had no more flu-like symptoms. Additional information has been requested.
First dose, had no reaction. Second dose, severe pain in arm, headache, back ache (lower, in proximity of kidneys), extreme tiredness, temperature over 99 degrees. This began approximately 18 hours after second dose. When the symptoms were at their worse, I went to bed and slept for over 4 hours. I felt better after I woke, however, the symptoms did not completely subside for an additional 6 hours.
administering a dose of Moderna COVID 19 vaccine to a 13 year-old; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (administering a dose of Moderna COVID 19 vaccine to a 13 year-old) in a 13-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jul-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (administering a dose of Moderna COVID 19 vaccine to a 13 year-old). On 27-Jul-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (administering a dose of Moderna COVID 19 vaccine to a 13 year-old) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided by the reporter.  No treatment information was provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 05-Aug-2021: Follow-up information included patient demographics added, suspect route and site added.
8PM not breathing, blue, limp, unresponsive, legs twitched; called MD @ 830; no other episode slept until 8PM from 4PM-no temp elevation;